Delivered-To: tjphuhs@gmail.com Received: by 2002:a05:6000:ace:b0:439:567a:e7b2 with SMTP id di14csp358769wrb; Tue, 24 Feb 2026 15:06:33 -0800 (PST) X-Received: by 2002:a05:6a20:5483:b0:38d:f8e6:fc9c with SMTP id adf61e73a8af0-39545fb3b95mr11705484637.69.1771974392884; Tue, 24 Feb 2026 15:06:32 -0800 (PST) ARC-Seal: i=1; a=rsa-sha256; t=1771974392; cv=none; d=google.com; s=arc-20240605; b=VGAQUlFOvdPl94NQy4X8vfIAE05m3jRhY5DTPbxtBiK/Vo1TDAhnPeaNoh+/z6Uq04 A1vD+VCZKFoUypSm0o++Aj5Y7Pgw2GQAMB2/75CfRH9aG2E9FewWNu/i7rtCiFGL+9z+ /bDtKvAU5ZBeQzEWOLxGOMn7gdQb1KWggt6kAXTLynT956RSFl0NsGFLljfaZpkF50NP CdPHRvnhDrhOdG8Eelu0U+lZU1BuUe5ZbavLyWpS9WCgBOiXopL5FZ+cXevthn4gN9OM 3uA07AH1G6BdDJbl3v5HNSlMk+ESwoiBsEjJye6ZsKmnxRzDt+cj50XY+5CUvnNLSQGi XBVQ== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=to:sid:list-unsubscribe-post:list-unsubscribe:feedback-id:reply-to :subject:message-id:mime-version:from:date:dkim-signature :dkim-signature; bh=XS4G+i72FDTYemwPo0Rw4iEXrMwI4mRNRh9s7kpNAAs=; fh=Hcu5VqhndQNvtVhwbc8tr7JrSOSQJms/+lG2L+E9gBs=; b=EMzboIRW3/l1swzTB2n2MRi8F1Bc7/IXpSX/00/H/i+1Yx/vsQ7996vWjq6Te4+9BK atQv48j24lYQ/nQ6eL1nzY210aClUKZtORnTHFJn71IwU8qtSzw2Ih1HJ65IDLXido1H xnNBJg1FYHtq4WKs6HHXXpFJD52AZsLJNEnLKXo7tvR/8wR/uWqoUHXu5YC3Pki5GvgJ godfmlByG7SiKZWgr1g+liQBYNpx68cGAxFRiYrENJ9urkUyshgvI3NhFQAtmUcinioq VkUT5MwY5DmppgBDfrap9HfBJBCReMVRT1BPWJmravDky+6LZn6tGgQ0V6daQRFiV4l8 GftQ==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@mail.beehiiv.com header.s=s1 header.b="i07E3+g/"; dkim=pass header.i=@sendgrid.info header.s=smtpapi header.b=RwZOTEGk; spf=pass (google.com: domain of bounces+38707395-e426-tjphuhs=gmail.com@em2003.mail.beehiiv.com designates 159.183.140.201 as permitted sender) smtp.mailfrom="bounces+38707395-e426-tjphuhs=gmail.com@em2003.mail.beehiiv.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=beehiiv.com Return-Path: Received: from o169.ptr1700.mail.beehiiv.com (o169.ptr1700.mail.beehiiv.com. [159.183.140.201]) by mx.google.com with ESMTPS id 41be03b00d2f7-c70b728cee4si15954970a12.210.2026.02.24.15.06.32 for (version=TLS1_3 cipher=TLS_AES_128_GCM_SHA256 bits=128/128); Tue, 24 Feb 2026 15:06:32 -0800 (PST) Received-SPF: pass (google.com: domain of bounces+38707395-e426-tjphuhs=gmail.com@em2003.mail.beehiiv.com designates 159.183.140.201 as permitted sender) client-ip=159.183.140.201; Authentication-Results: mx.google.com; dkim=pass header.i=@mail.beehiiv.com header.s=s1 header.b="i07E3+g/"; dkim=pass header.i=@sendgrid.info header.s=smtpapi header.b=RwZOTEGk; spf=pass (google.com: domain of bounces+38707395-e426-tjphuhs=gmail.com@em2003.mail.beehiiv.com designates 159.183.140.201 as permitted sender) smtp.mailfrom="bounces+38707395-e426-tjphuhs=gmail.com@em2003.mail.beehiiv.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=beehiiv.com DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=mail.beehiiv.com; h=content-type:date:from:mime-version:subject:reply-to:feedback-id: list-unsubscribe:list-unsubscribe-post:to:cc:content-type:date:feedback-id:from: subject:to; s=s1; bh=XS4G+i72FDTYemwPo0Rw4iEXrMwI4mRNRh9s7kpNAAs=; b=i07E3+g/pmRc+vyztmKb6dm6Olzt0IjeBf798oCKBfJCKJVLZLcf+KOfBlEG59l9gVGM /4Ty1WtAF8qWRLXSCCsawhHTY0+KoOR31DfN35JejEZvgk0HJtSdbgJ60b/twRrTKVaLOC rBgOawsMmiLW6bvQI90COSA6LB8XT+Hu4orpxv+BLRrjXTpQsPNBAkDR71q66t53Yms6a6 YacEQ+zP3Wj9ZKbtS8TCDWLhETswTcYTxnd+BXJTzLYd9qbzsjnKxj11sVcUvrs4a3nfi+ 08iZGAQx7RSxp1tE9edDtZ8MWRYpJ03qu51SHMzBX5IvjLgGHP2ps1RulQ0E+OUw== DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=sendgrid.info; h=content-type:date:from:mime-version:subject:reply-to:feedback-id: list-unsubscribe:list-unsubscribe-post:to:cc:content-type:date:feedback-id:from: subject:to; s=smtpapi; bh=XS4G+i72FDTYemwPo0Rw4iEXrMwI4mRNRh9s7kpNAAs=; b=RwZOTEGkbsRb6fohvALO59Do3wYpGRQlTifCMHsGup0nRF/nq55sNmgwUD+ZyL0pslhF P85SHfT5d7yzyOiF/pcCKUZVi7gQxfl0eAHeUoPOq0Sk0PAydxPf1S+k6CF6xCZDDXX4OP Qva0nMr4yJmdVdT0jo2Yj7LOAYsYH5wvE= Received: by recvd-6f6cf997fc-ptrcc with SMTP id recvd-6f6cf997fc-ptrcc-1-699E2EED-56 2026-02-24 23:06:21.421405733 +0000 UTC m=+5964924.595455666 Received: from Mzg3MDczOTU (unknown) by geopod-ismtpd-30 (SG) with HTTP id zwVxtWO8Q1iixgue6V35yA Tue, 24 Feb 2026 23:06:21.377 +0000 (UTC) Content-Type: multipart/alternative; boundary=fb9660bd613f1657a84d56bab7469549a40deb7dff9261e5cc2e892d4cfb Date: Tue, 24 Feb 2026 23:06:31 +0000 (UTC) From: Hunter Williams Mime-Version: 1.0 Message-ID: Subject: Reta vs. Cancer Reply-To: Hunter's Health Hacks Feedback-ID: =?us-ascii?Q?614881c8-5445-4b3f-8a99-f63898a772db=3Anewsletter=3Afd41630e-e91f-?= =?us-ascii?Q?46d9-a274-b740dab756d2=3Ac8f61fda6a60803?= List-Unsubscribe: =?us-ascii?Q?=3Cmailto=3Afd41630e-e91f-46d9-a274-b740dab756d2+9c40d639-6e1d-429?= =?us-ascii?Q?2-a9d7-0e4cbbb5d5db+614881c8-5445-4b3f-?= =?us-ascii?Q?8a99-f63898a772db=40unsub=2Ebeehiiv=2Ecom=3E=2C?= =?us-ascii?Q?_=3Chttps=3A=2F=2Fhuntershealthhacks=2Ebeehiiv=2Ecom=2Funsubscribe=2FeyJ0eXAiOi?= =?us-ascii?Q?JKV1QiLCJhbGciOiJIUzI1NiJ9=2EeyJzdWJzY3Jp?= =?us-ascii?Q?YmVyX2lkIjoiOWM0MGQ2MzktNmUxZC00MjkyLWE?= =?us-ascii?Q?5ZDctMGU0Y2JiYjVkNWRiIiwicG9zdF9pZCI6Ij?= =?us-ascii?Q?YxNDg4MWM4LTU0NDUtNGIzZi04YTk5LWY2Mzg5O?= =?us-ascii?Q?GE3NzJkYiIsImxhc3RfcmVzb3VyY2VfZ3VpZCI6?= =?us-ascii?Q?IlBvc3Q6NjE0ODgxYzgtNTQ0NS00YjNmLThhOTk?= =?us-ascii?Q?tZjYzODk4YTc3MmRiIn0=2El8a819MpXAZMXqrksI?= =?us-ascii?Q?F8cp8=5FctWAQXwgrIzeBVX-=5FVw=3E?= List-Unsubscribe-Post: List-Unsubscribe=One-Click sId: fd41630e-e91f-46d9-a274-b740dab756d2 x-beehiiv-ids: =?us-ascii?Q?{=22account=5Fname=22=3A=22https=3A=2F=2Fhuntershealthhacks=2Ebeehiiv=2Ecom=2F=22=2C=22cam?= =?us-ascii?Q?paign=5Fid=22=3A=22614881c8-5445-4b3f-8a99-f638?= =?us-ascii?Q?98a772db=22=2C=22category=22=3A=22newsletter=22=2C=22emai?= =?us-ascii?Q?l=5Fgenerated=5Fat=22=3A1771974381=2C=22user=5Fid=22=3A=22f?= =?us-ascii?Q?d41630e-e91f-46d9-a274-b740dab756d2=22}?= x-beehiiv-type: newsletter x-list-id: fd41630e-e91f-46d9-a274-b740dab756d2 x-list-owner: x-newsletter: https://huntershealthhacks.beehiiv.com/p/reta-vs-cancer x-newsletter-id: https://huntershealthhacks.beehiiv.com/ x-newsletter-signup: https://huntershealthhacks.beehiiv.com/subscribe X-SG-EID: =?us-ascii?Q?u001=2EVXMDIXn2fa+g+ucKwQBvoezrRjNBBJCTk8wFXvlJ6yYhrh=2F+ACKq8ZWJV?= =?us-ascii?Q?EO7veNaW5xH8Vxdm+c2ArDGcERy+LYNhm9ne4Sq?= =?us-ascii?Q?Tp6ejN4zu8GHTstuE5coeev=2FXdkXrSsNZkRuw6d?= =?us-ascii?Q?7En5B80O+JUX5AStBZiv8jG+ysM7eVdi4ZyN0QU?= =?us-ascii?Q?sS3Uw7MQ3guMjHf4CFrZ7BpnHQiacWfrryk57xY?= =?us-ascii?Q?nt0M2MyMXxXRIsDtQoPJDijvKxwn8ScMy13aC+h?= =?us-ascii?Q?3K7aXLF6Ne+TJ=2FYcq52eP+L=2FIg=3D=3D?= X-SG-ID: =?us-ascii?Q?u001=2ESdBcvi+Evd=2FbQef8eZF3BpTL9BgbK5wfSJMJGMsmprD1ZcmFObA4po1bG?= =?us-ascii?Q?aUE6gycKXL3zQZhXuUQn9tChysOltgtXWrvjRjU?= =?us-ascii?Q?3+ZCrxpYwjQQ8wEAUUyYSoOKXPjV8WtTr2gFeHO?= =?us-ascii?Q?p=2Fb0207MRPXzN4vhQR3l9JzYmiagtd7lm1k9iPS?= =?us-ascii?Q?GbYYeblSUvXaVJmGsKnOTN6h2TkFpOTG=2FCTfE7+?= =?us-ascii?Q?NpW2KVu91YoN9NQgjQN+5obeSIQnx++57WK4Yo7?= =?us-ascii?Q?3mNmq05V7I9tA+8PbOkIW9We7KAxUa6kfXaipYQ?= =?us-ascii?Q?heBCKlPFSNCxDy0N4iGA54rVIcsksSAxGQYEVJj?= =?us-ascii?Q?iCXQh4tIwMZEF+McsJ4UcsZJaENkNnTLEHOUpcy?= =?us-ascii?Q?0pZ22Y5EDZAWcWU?= To: "tjphuhs@gmail.com" X-Entity-ID: u001.gzTWOylKgaQyNgcScFpyNQ== --fb9660bd613f1657a84d56bab7469549a40deb7dff9261e5cc2e892d4cfb Content-Transfer-Encoding: quoted-printable Content-Type: text/plain; charset=utf-8 Mime-Version: 1.0 Happy Tuesday!=20 I recently came across [a preclinical study presented at the Society for Im= munotherapy of Cancer](https://jitc.bmj.com/content/13/Suppl_2/A752) that g= enuinely made me pause([click here to read it](https://jitc.bmj.com/content= /13/Suppl_2/A752)). The researchers looked at retatrutide and tested it in a mouse model of pan= creatic cancer.=20 The results were striking to say the least. Tumor growth was reduced to a d= egree comparable to that achieved with anti-PD1 immunotherapy. In simple terms, a metabolic drug commonly associated with obesity treatmen= t performed similarly to a frontline immune checkpoint cancer therapy in re= ducing tumor growth in this model. Interestingly, this study was not centered on dramatic weight loss or appet= ite suppression. The dose used did not significantly affect body weight, ye= t tumor growth decreased meaningfully. Retatrutide=E2=80=99s benefits go far beyond cosmetic fat loss.=20 They are metabolic. They are immunologic. They may even profoundly reshape = the body's internal terrain. =E2=80=9CFYI,=C2=A0[BioLongevity Labs=C2=A0](https://biolongevitylabs.com/)= is running a storewide sale where everything is 30% off. Use code HUNTERW t= o get an additional 15% off.=E2=80=9C =E2=80=94=20 =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94 **The Study** The researchers used obese mice with implanted pancreatic tumors.=20 Pancreatic cancer is one of the most aggressive and difficult cancers to tr= eat.=20 The mice were divided into groups. One group received no treatment. One rec= eived anti-PD1 immunotherapy. One received low-dose retatrutide. Another re= ceived both therapies together. The retatrutide group experienced about a 3X reduction in tumor volume. The= anti-PD1 group saw about a 5X reduction. The combination did not dramatica= lly outperform either therapy alone. What stands out is that the low-dose retatrutide dose did not cause meaning= ful weight loss. However, it did improve blood glucose levels. This suggests that tumor suppression was not simply due to reduced body fat= or calorie restriction.=20 Something about improving the body's metabolic environment altered tumor pr= ogression. When you improve glucose control, insulin signaling, inflammatory tone, and= cellular energy handling, you influence the biology that drives disease pr= ocesses. And cancer is deeply intertwined with metabolic dysfunction. =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94 **What This Could Mean for Humans** This was a mouse study, so we cannot definitively claim that retatrutide tr= eats or prevents cancer in people based on this data alone. We _can_ say that metabolism and cancer are closely linked.=20 Elevated insulin. Elevated glucose. Chronic inflammation. Visceral adiposit= y. Impaired immune surveillance. These factors create conditions that favor= tumor growth. If a compound improves glucose control, lowers inflammatory tone, enhances = insulin sensitivity, and potentially influences immune function, it is reas= onable to consider that it could support a less cancer-friendly internal en= vironment. Rather than viewing this through the lens of direct cancer therapy, it make= s sense to consider the overall environment within the body.=20 Retatrutide improves insulin sensitivity and reduces hyperglycemia. That sh= ift may reduce the availability of fuel and the growth signals that tumors = rely on. Even at lower doses, these metabolic changes may be meaningful. =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94 **Non-Cancer-Favoring Terrain** Cancer develops within biological terrain. * A body with high fasting glucose * A body with elevated insulin * A body with systemic inflammation * A body with immune dysfunction These conditions create fertile ground for pathological growth. Retatrutide appears to influence multiple pathways simultaneously.=20 It improves glucose regulation, flattens insulin spikes, reduces metabolic = stress, and may modulate immune signaling.=20 When glucose excursions are stabilized, glycation stress declines.=20 When insulin sensitivity improves, excessive anabolic growth signaling is r= educed.=20 When inflammatory tone decreases, immune surveillance may function more eff= iciently. This intersection of metabolism and immunity is often referred to as immuno= metabolism. Longevity is shaped by the environment in which cells operate. When that environment is stable, low inflammatory, insulin sensitive, and e= nergetically efficient, it becomes less supportive of pathological processe= s. =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94 **The Microdose Longevity Perspective** Most people associate retatrutide with aggressive fat loss protocols involv= ing higher weekly doses and significant appetite suppression. There is another way to look at this. Instead of focusing solely on weight loss, we can focus on metabolic optimi= zation.=20 A microdose under 2 mg per week may not produce dramatic appetite suppressi= on or rapid fat reduction.=20 However, based on what we understand about its mechanisms, it could still i= mprove glucose handling and metabolic stability. Longevity is built on reducing chronic metabolic stress over the course of = decades.=20 If a small weekly dose helps stabilize blood sugar, improve insulin sensiti= vity, and lower systemic stress without excessive suppression of appetite o= r energy, that becomes a sustainable strategy. Consistency matters more than intensity. Subtle improvements maintained ove= r the years can compound in powerful ways. =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94 **Reta Beyond Fat Loss** For years, I have emphasized that GLP-1 agents are metabolic regulators rat= her than simple fat loss drugs.=20 Retatrutide extends that concept because of its triple receptor activity. B= y influencing GLP-1, GIP, and glucagon signaling, it reshapes energy handli= ng at the systems level. The cancer model reinforces the idea that improving metabolic health can br= oadly influence chronic disease pathways, including those involved in tumor= biology. If low-dose retatrutide can meaningfully reduce tumor progression in an agg= ressive cancer model without causing weight loss, that suggests its metabol= ic influence runs deeper than body composition changes alone. That opens the door to considering this molecule within a broader longevity= framework. =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94 **Final Thoughts** We are still early in the research. Human data will be essential before dra= wing firm conclusions. Even so, the data's direction is compelling.=20 Improving metabolic signaling alone influenced tumor biology in this model.= That reinforces the central role of insulin resistance, hyperglycemia, and= chronic inflammation in disease progression. For those focused on long-term health, the goal extends beyond leanness.=20 The objective is metabolic resilience. Stable glucose. Controlled insulin. = Low inflammatory tone. Effective immune surveillance. If a microdose of retatrutide under 2 mg per week can help support that env= ironment without extreme appetite suppression or muscle loss, it becomes a = strategic tool within a longevity framework. Steady metabolic optimization over time may prove more impactful at solving= the cancer epidemic than we could ever have imagined! Best, Hunter Williams=20 =E2=80=94=E2=80=94=E2=80=94 You are reading a plain text version of this post. For the best experience,= copy and paste this link in your browser to view the post online: https://huntershealthhacks.beehiiv.com/p/reta-vs-cancer --fb9660bd613f1657a84d56bab7469549a40deb7dff9261e5cc2e892d4cfb Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset=utf-8 Mime-Version: 1.0 Reta vs. Cancer<= body class=3D"a" style=3D"margin:0px auto;padding:0px;word-wrap:normal;word= -spacing:normal;background-color:#FFFFFF;">
New s= tudy just released  ‌ ‌ ‌ ‌= 0;‌ ‌ ‌ ‌ ‌ ‌&= #160;‌ ‌ ‌ ‌ ‌ ̴= 4; ‌ ‌ ‌ ‌ ‌ &#= 8204; ‌ ‌ ‌ ‌ ‌ = ;‌ ‌ ‌ ‌ ‌ ‌&#= 160;‌ ‌ ‌ ‌ ‌ ‌= ; ‌ ‌ ‌ ‌ ‌ = 204; ‌ ‌ ‌ ‌ ‌ = ‌ ‌ ‌ ‌ ‌ ‌= 60;‌ ‌ ‌ ‌ ‌ ‌=  ‌ ‌ ‌ ‌ ‌ R= 04; ‌ ‌ ‌ ‌ ‌ &= #8204; ‌ ‌ ‌ ‌ ‌= 0;‌ ‌ ‌ ‌ ‌ ‌&= #160;‌ ‌ ‌ ‌ ‌ ̴= 4; ‌ ‌ ‌ ‌ ‌ &#= 8204; ‌ ‌ ‌ ‌ ‌ = ;‌ ‌ ‌ ‌ ‌ ‌&#= 160;‌ ‌ ‌ ‌ ‌ ‌= ; ‌ ‌ ‌ ‌ ‌ = 204; ‌ ‌ ‌ ‌ ‌ = ‌ ‌ ‌ ‌ ‌ ‌= 60;‌ ‌ ‌ ‌ ‌ ‌=  ‌ ‌ ‌ ‌ ‌ R= 04; ‌ ‌ ‌ ‌ ‌ &= #8204; ‌ ‌ ‌ ‌ ‌= 0;‌ ‌ ‌ ‌ ‌ ‌&= #160;‌ ‌ ‌ ‌ ‌ ̴= 4; ‌ ‌ ‌ ‌ ‌ &#= 8204; ‌ ‌ ‌ ‌ ‌ = ;‌ ‌ ‌ ‌ ‌ ‌&#= 160;‌ ‌ ‌ ‌ ‌ ‌= ; ‌ ‌ ‌ ‌ ‌ = 204; ‌ ‌ ‌ ‌ ‌ =
= <= td class=3D"dd" align=3D"left" style=3D"padding:0px 15px;text-align:left;wo= rd-break:break-word;">

When inflammatory tone decreases, immune surveillanc= e may function more efficiently.

= =

We are still early in the research. Human data will = be essential before drawing firm conclusions.

February 24, 2026   | &= nbsp; Read Online=

Reta vs. Cancer

New study just released=

3D"share
= 		 
3D"share
 
3D"share
 
3D"share=
3D""
=
= = = <= td class=3D"dd" align=3D"left" style=3D"padding:0px 15px;text-align:left;wo= rd-break:break-word;">

Even at lower doses, these metabolic changes may be = meaningful.

Happy Tuesday!

I recently came across a preclinical study presented at the Society = for Immunotherapy of Cancer that genuinely made me pause(= click here to read it).

The researche= rs looked at retatrutide and tested it in a mouse model of pancreatic cance= r.

The results were strikin= g to say the least. Tumor growth was reduced to a degree comparable to that= achieved with anti-PD1 immunotherapy.

In simple terms, a metabolic drug commonly associated with obesi= ty treatment performed similarly to a frontline immune checkpoint cancer th= erapy in reducing tumor growth in this model.

Interestingly, this study was not centered on dramatic we= ight loss or appetite suppression. The dose used did not significantly affe= ct body weight, yet tumor growth decreased meaningfully.

Retatrutide=E2=80=99s benefits go far beyond c= osmetic fat loss.

They are= metabolic. They are immunologic. They may even profoundly reshape the body= 's internal terrain.

FYI,= =C2=A0BioLongevity L= abs=C2=A0is running a s= torewide sale where everything is 30% off. Use code HUNTERW to get an addit= ional 15% off.

=
 

T= he Study

The researcher= s used obese mice with implanted pancreatic tumors.

Pancreatic cancer is one of the most aggressive an= d difficult cancers to treat.

The mice were divided into groups. One group received no treatment. One = received anti-PD1 immunotherapy. One received low-dose retatrutide. Another= received both therapies together.

The retatrutide group experienced about a 3X reduction in tumor volu= me. The anti-PD1 group saw about a 5X reduction. The combination did not dr= amatically outperform either therapy alone.

What stands out is that the low-dose retatrutide dose did n= ot cause meaningful weight loss. However, it did improve blood glucose leve= ls.

This suggests that tumor= suppression was not simply due to reduced body fat or calorie restriction.=

Something about improving = the body's metabolic environment altered tumor progression.

<= /td>

When you improve glucose control, insul= in signaling, inflammatory tone, and cellular energy handling, you influenc= e the biology that drives disease processes.

And cancer is deeply intertwined with metabolic dysfunctio= n.

 

What This Could Mean for Humans

= This was a mouse study, so we cannot defi= nitively claim that retatrutide treats or prevents cancer in people based o= n this data alone.

We can say that metabolism and cancer are closely linked.

=

Elevated insulin. Elevated glucose. Ch= ronic inflammation. Visceral adiposity. Impaired immune surveillance. These= factors create conditions that favor tumor growth.

If a compound improves glucose control, lowers infl= ammatory tone, enhances insulin sensitivity, and potentially influences imm= une function, it is reasonable to consider that it could support a less can= cer-friendly internal environment.

Rather than viewing this through the lens of direct cancer therapy, = it makes sense to consider the overall environment within the body. =

Retatrutide improves insulin sensi= tivity and reduces hyperglycemia. That shift may reduce the availability of= fuel and the growth signals that tumors rely on.

 

Non-Cancer-Favoring Terrain

Cancer develops within biological te= rrain.

  • A body with high fasting glucose

    =

  • A body with elevated insulin

  • A body with syst= emic inflammation

  • A body with immune dysfunction=

These conditions c= reate fertile ground for pathological growth.

Retatrutide appears to influence multiple pathways simult= aneously.

It improves gluco= se regulation, flattens insulin spikes, reduces metabolic stress, and may m= odulate immune signaling.

When glucose excursions are stabilized, glycation stress declines. =

When insulin sensitivity improves,= excessive anabolic growth signaling is reduced.

This intersection of metabolism and immunity is often referred to as i= mmunometabolism. Longevity is shaped by the environment in which cells oper= ate.

When that environment i= s stable, low inflammatory, insulin sensitive, and energetically efficient,= it becomes less supportive of pathological processes.

 

The Microdose Longevity Perspective

Most people associate retatrutide with aggressive fat loss = protocols involving higher weekly doses and significant appetite suppressio= n.

There is another way to l= ook at this.

Instead of foc= using solely on weight loss, we can focus on metabolic optimization.

A microdose under 2 mg per week m= ay not produce dramatic appetite suppression or rapid fat reduction.

However, based on what we underst= and about its mechanisms, it could still improve glucose handling and metab= olic stability.

Longevity is= built on reducing chronic metabolic stress over the course of decades.

If a small weekly dose helps s= tabilize blood sugar, improve insulin sensitivity, and lower systemic stres= s without excessive suppression of appetite or energy, that becomes a susta= inable strategy.

Consistency= matters more than intensity. Subtle improvements maintained over the years= can compound in powerful ways.

 

Reta Beyond Fat Loss=

For years, I have empha= sized that GLP-1 agents are metabolic regulators rather than simple fat los= s drugs.

Retatrutide extend= s that concept because of its triple receptor activity. By influencing GLP-= 1, GIP, and glucagon signaling, it reshapes energy handling at the systems = level.

The cancer model rein= forces the idea that improving metabolic health can broadly influence chron= ic disease pathways, including those involved in tumor biology.

<= /td>

If low-dose retatrutide can meaningfull= y reduce tumor progression in an aggressive cancer model without causing we= ight loss, that suggests its metabolic influence runs deeper than body comp= osition changes alone.

That = opens the door to considering this molecule within a broader longevity fram= ework.

 

Final Thoughts

Even so, the data's direction is compelling. <= /p>

Improving metabolic signaling alone= influenced tumor biology in this model. That reinforces the central role o= f insulin resistance, hyperglycemia, and chronic inflammation in disease pr= ogression.

For those focused= on long-term health, the goal extends beyond leanness.

The objective is metabolic resilience. Stable = glucose. Controlled insulin. Low inflammatory tone. Effective immune survei= llance.

If a microdose of re= tatrutide under 2 mg per week can help support that environment without ext= reme appetite suppression or muscle loss, it becomes a strategic tool withi= n a longevity framework.

Ste= ady metabolic optimization over time may prove more impactful at solving th= e cancer epidemic than we could ever have imagined!

Best,

Hunter Williams

=
<= /tr><= tr><= tr>
3D"ig"3D"yt"
3D""
<= h2 style=3D"color:#2A2A2A;font-weight:normal;mso-line-height-alt:150.0%;"><= span style=3D"font-size:1.5rem;">Want more? Here=E2=80=99s how you can work= with me:

=F0=9F=91=89Join my private coaching group, The AXION Collective= :

=F0=9F=91=89Try Zeroats, the world=E2=80=99s first sugar-fr= ee, naturally flavored oatmeal:

=F0=9F=91=89Get the Pept= ide Cheat Sheet:

=F0=9F=91=89All my daily essentials on Amazon

=F0=9F=91=89Get discounts on your= favorite peptides and research chemicals:

=F0=9F=91=8910% off the BEST workout supplements from Unmatc= hed Supps (pre-workout, whey protein, creatine, EAAs, electrolytes - use co= de HUNTERW at checkout):

=F0=9F=91=89Submit A = Video Topic For My Next YouTube Video:

Update your email preferences or unsubscr= ibe here

© 2026 Hu= nter's Health Hacks

228 Park Ave S, #29976, New York, New York = 10003, United States

3D"beehi=Powered by beehiiv
Terms of Service
<= /div> --fb9660bd613f1657a84d56bab7469549a40deb7dff9261e5cc2e892d4cfb--